Ladly Abraham, MD
Pulmonary Disease · Conway, ARNPI 1972537090
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $270,870 of the $370,709 with a category attached, or 73.1%. 45 manufacturers reported payments, led by AstraZeneca at 49.8% of the total. Among pulmonary disease clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,348 payments — averaging $275.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$185K
- GSK$113K
- Sunovion Pharmaceuticals Inc.$19K
- Boehringer Ingelheim$19K
- Verona Pharma, Inc.$9K
- United Therapeutics Corporation$6K
- plus $19K from 39 others
Across 112 payments — averaging $1339.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$80K
- Insmed, Inc.$36K
- Teva Pharmaceuticals USA, Inc.$17K
- United Therapeutics Corporation$13K
- GSK$4K
What the payments were for
- Consulting fees$21,0236%
- Speaking & faculty fees$270,87073%
- Travel & lodging$47,48513%
- Food & beverage$30,9358%
- Education$3960%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$94,945
- AIRSUPRA$78,530
- AREXVY$63,224
- LONHALA MAGNAIR$18,349
- TRELEGY ELLIPTA$12,310
- Ohtuvayre$9,115
- NUCALA$8,618
- ANORO$6,065
- TYVASO$5,683
- Yupelri$4,286
- BREZTRI AEROSPHERE$3,017
- FASENRA$1,797
- The Monarch Airway Clearance System$875
- The Vest System Model 105 Home Care$875
- The Vest System 205 Acute Care$875
- GALAXY$639
- UPTRAVI$495
- OPSUMIT$495
- XARELTO$237
- Cios Spin$235
How this compares
$370,709 in reported general payments places this provider in the 95th percentile of 102 pulmonary disease providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 2,033 | $1,641,401 |
| OpsumitMacitentan | 115 | $1,432,372 |
| UptraviSelexipag | 36 | $736,990 |
| Prolastin CAlpha-1-Proteinase Inhibitor | 52 | $674,484 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 771 | $573,080 |
| OfevNintedanib Esylate | 36 | $463,179 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 448 | $240,191 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 373 | $210,960 |
| Breo ElliptaFluticasone/Vilanterol | 273 | $131,883 |
| Spiriva RespimatTiotropium Bromide | 140 | $86,381 |
| SymbicortBudesonide/Formoterol Fumarate | 267 | $85,586 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 139 | $72,984 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 2,415 | $65,053 |
| Dupixent PenDupilumab | 12 | $48,727 |
| Spiriva HandihalerTiotropium Bromide | 75 | $48,651 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Opsumit, Uptravi | $1,794 | $2,169,362151 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $113,469 | $2,034,4332,808 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $18,897 | $784,846585 claims |
| AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere | $184,624 | $731,6491,177 claims |
| Grifols USA, LLCProlastin C | $1,148 | $674,48452 claims |
| PfizerEliquis | $50 | $30,71938 claims |
| Johnson & JohnsonXarelto | $282 | $8,01812 claims |
| MerckDulera | $214 | $4,50211 claims |
| Teva Pharmaceuticals USA, Inc.Proair Respiclick | $15 | $2,51437 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 102 pulmonary disease providers in Arkansas.
Other pulmonary disease in Conway
- Raga Deepak Reddy PalagiriConway$4K
- Tyrone LeeConway$4K
- Daniel PaulRogers$244K
- Jason McKinneyRogers$86K
- Arturo MeadeFort Smith$67K
- Nikhil MeenaLittle Rock$63K
- Penchala MittadodlaRogers$21K
- Mark SiffordJonesboro$20K
- Zafirah SalmanNorth Little Rock$18K
- Dominika SzwedoNorth Little Rock$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.